What is the appropriate management for hand, foot, and mouth disease?

Management of Hand, Foot, and Mouth Disease

Hand, foot, and mouth disease (HFMD) is managed primarily with supportive care focused on hydration and pain relief, as no specific antiviral therapy is currently approved for routine use.

Core Management Principles

The management of HFMD is fundamentally supportive, targeting symptom relief while the viral illness runs its self-limited course 1, 2. Most cases resolve spontaneously within 7-10 days without sequelae 1, 2.

Symptomatic Treatment

Pain and fever management should utilize acetaminophen or ibuprofen 2. Oral lidocaine is specifically not recommended due to safety concerns 2. The primary therapeutic goals are:

• Adequate hydration: Critical given painful oral ulcerations that may impair oral intake
• Pain control: To facilitate eating and drinking
• Fever management: Using standard antipyretics

Outpatient vs. Inpatient Management

Most mild cases can be managed as outpatients 3. The key decision point is identifying which patients require hospitalization based on severity staging:

Indicators for Hospitalization (Severe Disease Warning Signs):

Monitor closely for these red flags that signal potential progression to severe/critical disease 3:

1. Persistent hyperthermia despite antipyretics
2. Neurological involvement: lethargy, myoclonus, tremors, ataxia, or altered consciousness
3. Respiratory compromise: tachypnea, irregular breathing patterns
4. Circulatory dysfunction: tachycardia, poor perfusion, mottled skin
5. Laboratory abnormalities: elevated WBC count, hyperglycemia, elevated lactate

Children under 3 years with EV-A71 infection and disease duration less than 3 days require particularly close monitoring 3, as they are at highest risk for rapid deterioration.

Isolation and Infection Control

Patients should be isolated to prevent cross-infection 3. The disease spreads via:

• Fecal-oral transmission
• Oral-oral contact
• Respiratory droplets

The most effective preventive measures are handwashing and disinfecting contaminated surfaces and fomites 2.

Controversial Therapies: What NOT to Use Routinely

Steroids and IVIG

There is a significant divergence in international guidelines. While Chinese national guidelines recommend steroids and intravenous immunoglobulin (IVIG) for severe cases 4, WHO and US-CDC guidelines do not support their routine use 4.

A nine-year retrospective study showed:

• No significant advantage of steroids or IVIG in mild cases 4
• Longer hospital stays associated with steroid/IVIG use in severe cases 4
• Lower recovery rates with IVIG use in mild cases 4

IVIG should only be considered for severe/complicated HFMD 1, not for routine mild-to-moderate disease.

Antiviral Agents

Currently, no specific antiviral agents are approved for HFMD treatment 1, 2. Drugs like ribavirin, suramin, and sertraline have emerged as potential candidates but remain investigational 1. One case report suggested valacyclovir may provide benefit in adults 5, but this is anecdotal and requires validation.

Severe Disease Management

For patients progressing to stages 2-3 (nervous system involvement) or stage 4 (cardiopulmonary failure):

• Intensive care unit admission
• Advanced supportive therapies targeting:
  • Neurogenic pulmonary edema (main cause of death from brainstem damage)
  • Circulatory failure from myocardial impairment
• Consider IVIG in this context 1

Prevention Strategies

Primary prevention includes 6, 1:

• Hand hygiene education
• Breastfeeding promotion
• Environmental sanitation
• Avoidance of contact with infected individuals

Vaccination: Inactivated EV-A71 vaccines developed in China demonstrate over 90% efficacy in preventing severe HFMD 6. These should be considered for susceptible individuals in high-risk areas 1.

Common Pitfalls to Avoid

1. Do not use oral lidocaine for pain management 2
2. Do not routinely prescribe steroids or IVIG for mild cases - evidence shows no benefit and potential harm 4
3. Do not miss early warning signs of severe disease progression, particularly in high-risk children (age <3 years, EV-A71 infection, disease duration <3 days) 3
4. Do not assume all vesicular rashes are HFMD - maintain broad differential including varicella, herpes, erythema multiforme 2, 7

Monitoring and Follow-up

Active communication and close monitoring are integral to preventing complications 8. Parents should be counseled on:

• Expected disease course (7-10 days)
• Warning signs requiring immediate medical attention
• Hydration strategies
• Infection control measures at home